Eli Lilly & Co.’s experimental Alzheimer’s treatment failed to slow the progression of the neurodegenerative disease, another setback for drugmakers and researchers trying to develop treatments for one of the world’s most feared ailments.
Patients given solanezumab didn’t show a meaningful slowing of cognitive decline compared with those who got a placebo, Lilly said in a statement Wednesday. The drugmaker said it wouldn’t file for regulatory approval of the medicine and hasn’t decided what steps it will take next for trials that are still underway.
